Neuroendocrine tumors: A population-based study of incidence and survival in Girona province, 1994-2004

Cancer Epidemiology

Volumn 35, Issue 6, 2011, Pages

  Alsina, Maria ^a   Marcos Gragera, Rafael ^b   Capdevila, Jaume ^a   Buxó, Maria ^b,c,d   Ortiz, Rosa Maria ^e   Barretina, Pilar ^e   Vilardell, Loreto ^b   Brunet, Joan ^e   Beltran, Miquel ^e   Izquierdo, Àngel ^b,e  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^c UNIVERSITAT POMPEU FABRA   (Spain)

^d UNIVERSITY OF GIRONA   (Spain)

^e HOSPITAL JOSEP TRUETA   (Spain)

Author keywords

Incidence; Neuroendocrine tumor; Survival

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER INCIDENCE; CANCER REGISTRY; CANCER SURVIVAL; CARCINOID; CHILD; DIGESTIVE SYSTEM CANCER; ENDOCRINE TUMOR; FEMALE; HUMAN; INFANT; LUNG CARCINOMA; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MERKEL CELL TUMOR; MORPHOLOGY; NEUROENDOCRINE TUMOR; PANCREAS CANCER; PHEOCROMOCYTOMA; POPULATION RESEARCH; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SPAIN;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INCIDENCE; INFANT; MALE; MIDDLE AGED; NEUROENDOCRINE TUMORS; SPAIN; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 81055157913     PISSN: 18777821     EISSN: 1877783X     Source Type: Journal    
DOI: 10.1016/j.canep.2011.05.011     Document Type: Article

References (47)

1. Langley K. The neuroendocrine concept today. Ann N Y Acad Sci 1994, 733:1-17.
2. Barakat M.T., Meeran K., Bloom S.R. Neuroendocrine tumours. Endocr Relat Cancer 2004, 11(1):1-18.
3. Kloppel G. Tumour biology and histopathology of neuroendocrine tumours. Best Pract Res Clin Endocrinol Metab 2007, 21(1):15-31.
4. Astudillo A. Clasificación y caracterización biológica de los tumores neuroendocrinos del tracto gastrointestinal. Oncología 2004, 27(4):179-184.
5. Hemminki K., Li X. Incidence trends and risk factors of carcinoid tumors: a nationwide epidemiologic study from Sweden. Cancer 2001, 92(8):2204-2210.
6. Levi F., Te V.C., Randimbison L., Rindi G., La V.C. Epidemiology of carcinoid neoplasms in Vaud, Switzerland, 1974-97. Br J Cancer 2000, 83(7):952-955.
7. Modlin I.M., Lye K.D., Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer 2003, 97(4):934-959.
8. Newton J.N., Swerdlow A.J., dos S.S., Vessey M.P., Grahame-Smith D.G., Primatesta P., et al. The epidemiology of carcinoid tumours in England and Scotland. Br J Cancer 1994, 70(5):939-942.
9. Taal B.G., Visser O. Epidemiology of neuroendocrine tumours. Neuroendocrinology 2004, 80(Suppl 1):3-7.
10. Yao J.C., Hassan M., Phan A., Dagohoy C., Leary C., Mares J.E., et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008, 26(18):3063-3072.
11. Crocetti E., Buiatti E., Amorosi A. Epidemiology of carcinoid tumours in central Italy. Eur J Epidemiol 1997, 13(3):357-359.
12. Niccoli P., Raoul J., Bang Y., Borbath I., Lombard-Bohas C., Valle J.W., et al. Updated safety and efficacy results of the phase III trial of sunitinib (SU) versus placebo (PBO) for treatment of pancreatic neuroendocrine tumors (NET). J Clin Oncol 2010, 28(Suppl 15):4000.
13. Yao J.C., Shah M.H., Ito T., Lombard Bohas C., Wolin E.M., Van Cutsem E., et al. Everolimus for Advanced Pancreatic Neuroendocrine Tumors N Engl J Med 2011, 364(Feb):514-523.
14. Klimstra D.S., Modlin I.R., Coppola D., Lloyd R.V., Suster S. The pathologic classification of neuroendocrine tumors. A review of nomenclature, grading, and staging systems. Pancreas 2010, 39:707-712.
15. Berge T., Linell F. Carcinoid tumours. Frequency in a defined population during a 12-year-period. Acta Path Microbiol Scand Sect A 1976, 84:322-330.
16. Viladiu P., Izquierdo A., Marcos R., Vilardell L., Moreno V., Bosch X., et al. Cancer incidence in Girona (Spain) 1993-1997. Cancer incidence in five continents 2002, vol. VIII.
17. Esteve J., Benhamou E., Raymond L. Descriptive epidemiology. Statistical methods in cancer research 1994, vol. IV. IARC Scientific Publications/World Health Organisation, Lyon.
18. Esteve J., Benhamou E., Croasdale M., Raymond L. Relative survival and the estimation of net survival. Elements for further discussion. Stat Med 1990, 9:529-538.
19. Hakulinen T. Cancer survival corrected for heterogeneity in patients withdrawal. Biometrics 1982, 38:933-942.
20. Clèries R., Ribes J., Gálvez J., Melià A., Moreno V., Bosch F.X. Cálculo automatizado de la supervivencia relativa vía web. El proyecto WAERS del Instituto Catalán de Oncología. Gac Sanit 2005, 19:71-75.
21. Oberndorfer Karzinoide Tumoren des Dünndarms. Frankf Z Pathol 1907, 1:425-432.
22. Villiams E.D., Sandler M. The classification of carcinoid tumours. Lancet 1963, 1(7275):238-239.
23. Travis W.D., Colby T.V., Corrin B., Shimosato Y., Brambilla E. Collaboration with Sobin LH and pathologists from 14 countries. Histological typing of lung and pleural tumours. World Health Organization International Histological Classification of Tumours. Histological tying of lung and pleural tumours 1999, Springer-Verlag, Berlin. 3rd ed.
24. Brambilla E., Travis W.D., Colby T.V., Corrin B., Shimosato Y. The New World Health Organization Classification of Lung Tumours. Eur Respir J 2001, 18:1059-1068.
25. Aranda F., Alenda C., Perió F.M., Perió G. Tumores neuroendocrinos pulmonares. Rev Esp Patol 2003, 36(4):389-404.
26. Younossian A.B., Brundler M.A., Totsch M. Feasibility of the new WHO classification of pulmonary neuroendocrine tumours. Swiss Med Wkly 2002, 132(37-38):535-540.
27. Histological typing of endocrine tumours. WHO International Histological Classification of Tumours 2000, Springer, Berlin. 2nd ed. Solcia, Kloppel, Sobin (Eds.).
28. Kloppel G., Perren A., Heitz P.U. The gastroenteropancreatic neuroendocrine cell system and its tumors: the WHO classification. Ann N Y Acad Sci 2004, 1014:13-27.
29. Rindi G., Capella C., Solcia E. Introduction to a revised clinicopathological classification of neuroendocrine tumors of the gastroenteropancreatic tract. Q J Nucl Med 2000, 44(1):13-21.
30. Rindi G., Kloppel G., Alhman H., Caplin M., Couvelard A., de Herder W.W., et al. TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch 2006, 449(4):395-401.
31. Rindi G., Kloppel G., Couvelard A., Komminoth P., Korner M., Lopes J.M., et al. TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Arch 2007, 451(4):757-762.
32. Edge S.B., Byrd D.R., Compton C.C. AJCC cancer staging manual 2010, Springer-Verlag, New York. 7th ed.
33. Quaedvlieg P.F.H.J., Visser O., Lamers C.B.H.W., Janssen-Heijen M.L.G., Taal B.G. Epidemiology and survival in patients with carcinoid disease in the Netherlands. An epidemiological study with 2391 patients. Ann Oncol 2001, 12:1295-1300.
34. Instituto Nacional de Estadística. Cifras de Población y Censos Demográficos. Madrid. Available from: [accessed 06 April 2011]. http://www.ine.es/jaxi/tabla.do%3Fpath=/t15/p419/p02/a2003/l0/%26file=02001.px%26type=pcaxis.
35. Skuladottir H., Hirsch F.R., Hansen H.H., Olsen J.H. Pulmonary neuroendocrine tumors: Incidence and prognosis of histological subtypes. A population-based study in Denmark. Lung Cancer 2002, 37:127-135.
36. DeVita V.T., Hellman S., Rosenberg S.A. Cancer, principles and practice of oncology 2005, Lippincott Williams and Wilkins, Philadelphia. 7th ed.
37. Govidan R., Page N., Morgensztern D., Read W., Tierney R., Vlahiotis A., et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 2006, 24(28):4539-4544.
38. Cabanes A., Pérez-Gómez B., Aragonés N. La situación del Cáncer en España 1975-2006 2009, Centro Nacional de Epidemiología-Instituto de Salud Carlos III, Madrid. 1st ed.
39. Lepage C., Bouvier A.M., Phelip J.M. Incidence and management of malignant digestive endocrine tumours in a well defined French population. Gut 2004, 53:549-553.
40. Garcia-Carbonero R., Capdevila J., Crespo-Herrero G. Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the National Cancer Registry of Spain (RGETNE). Ann Oncol 2010 Sep, 21(9):1794-1803.
41. Biersack H.J., Grünwald F. Thyroid cancer 2005, Springer-Verlag, Berlin/Heidelberg/New York. 2nd ed.
42. Hundahl S.A., Fleming I.D., Fremgen A.M., Menck H.R. Two hundred eighty six cases of parathyroid carcinoma treated in the US between 1985-1995: a National Cancer Data Base Report. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer 1999, 86:538-544.
43. Chen H., Sippel R.S., O'Dorisio M.S. The North American Neuroendocrine Tumor Society Consensus Guideline for the Diagnosis and Management of Neuroendocrine Tumors. Pheocromocytoma, paraganglia, and medullary thyroid cancer. Pancreas 2010, 39(6):775-783.
44. DeLellis R.A., Lloyd R.V., Heitz P.U. Pathology & genetics. Tumors of endocrine organs. World Health Organization Classification of Tumors 2004, IARC Press, Lyon. 1st ed.
45. Kaae J., Hansen A.V., Biggar R.J. Merkel cell carcinoma: incidence, mortality, and risk of other cancers. J Natl Cancer Inst 2010, 102(11):793-801.
46. Agelli M., Clegg L.X. Epidemiology of primary Merkel cell carcinoma in the United States. J Am Acad Dermatol 2003, 49:832-841.
47. Vila-Coromina N., Perez-Bueno F., Alsina M. Merkel cell cancer of the skin: population-based incidence and survival, 1995-2005. Med Clin 2009, 132(18):701-703.